Positive Patient Stories™

Paratek Pharmaceuticals News

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle  
04/19/18Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024 
04/18/18Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024 
04/13/18Paratek Appoints Rolf K. Hoffmann to Company’s Board of Directors 
04/12/18Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018 
04/04/18Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA 
03/30/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
03/28/18Paratek Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference 
03/16/18Paratek Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference 
03/02/18Paratek Pharmaceuticals to Present at the 38th Annual Cowen & Co. Health Care Conference 
03/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
03/01/18Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019 
02/15/18Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018 
02/05/18Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections 
02/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
01/31/18Paratek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Healthcare Conference 
01/18/18Paratek Announces Pricing of Public Offering of Common Stock 
01/17/18Paratek Announces Public Offering of Common Stock 
01/03/18Paratek Provides Update on Pipeline Progress 

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.